Plachetka offered no details on exactly how the deal happened other than to say that Pozen has been supportive of AstraZeneca exercising its options under the Vimovo licensing agreement to assign the Vimovo's rights to another company. Plachetka said the terms of the original license gave Pozen the right to consent to that assignment and Pozen has done so.